NASCENT BIOTECH INC - NBIO STOCK NEWS

Nascent Biotech (OTCQB:NBIO) has successfully settled its convertible note liability with Harbor Gate Capital LLC, eliminating a potential dilution risk for shareholders. The settlement involved a total value of $115,000, covering principal, accrued interest, and prepayment. As a result, the company has almost eradicated outstanding dilution risks associated with previous funding rounds. Additionally, all preferred shares from prior convertible financing have been converted, with only one convertible note remaining, due in August 2021.

Nascent Biotech, Inc. (OTCQB:NBIO) has successfully eliminated a significant convertible debt of over $186k held by JSJ Investments, LLC. This proactive measure prevents potential dilution of shares that could arise from the conversion of this debt into common shares at a discounted rate. CEO Sean Carrick emphasized the company’s commitment to shareholder value and reducing uncertainty in its financial standing. Nascent Biotech is focused on developing monoclonal antibodies for treating various cancers and viral infections, with ongoing clinical trials for their lead candidate, Pritumumab.

Nascent Biotech (OTCQB:NBIO) has initiated patient dosing in its Phase I clinical trial for Pritumumab (PTB), aimed at treating brain cancer including malignant tumors and brain metastases. This milestone is crucial for assessing PTB's safety and efficacy. The antibody targets cancer cells by binding to vimentin, offering a potential alternative to traditional chemotherapy. As enrollment continues, the trial may influence future studies for common cancers like breast and lung cancer. For more information, visit ClinicalTrials.gov.

Nascent Biotech has commenced its Phase I clinical trial for Pritumumab (PTB), focusing on treating brain cancer, including malignant primary brain tumors and brain metastases. The trial aims to evaluate PTB's effectiveness as a targeted immunotherapy, which selectively targets cancer cells without affecting healthy cells. Screening for patient enrollment is ongoing. This trial could open pathways for treating various cancers, given that the antibody binds to a protein present in multiple cancer types. For more details, visit clinicaltrials.gov.

Nascent Biotech (OTCQB:NBIO) has received a Method-of-Use patent from the USPTO for its monoclonal antibody, Pritumumab (PTB). This patent highlights PTB's ability to cross the Blood-Brain Barrier (BBB), enhancing its potential as both a monotherapy and a carrier for other treatments. The approval strengthens the company's intellectual property and market position, crucial for its expansion in cancer and viral therapies. CEO Sean Carrick emphasized the significance of this patent for potential market impact and future updates for shareholders.

Nascent Biotech (OTCQB:NBIO) has reported promising results from its collaboration with Syracuse University, showcasing that its monoclonal antibody, Pritumumab (PTB), effectively blocked 80% of viral entry into cells. This breakthrough allows PTB to advance to laboratory-based animal studies, potentially aiding in COVID-19 treatment. The research highlights PTB's mechanism of action by targeting cell-surface vimentin to inhibit SARS2 entry. The company also launched a Phase I Clinical Trial for Brain Cancer at Hoag Family Cancer Institute, showing commitment to developing treatments for cancers and viral infections.

Nascent Biotech (OTCQB:NBIO) has announced positive initial In-Vitro study results in collaboration with Syracuse University, demonstrating that Pritumumab (PTB) effectively blocks viral entry of SARS-CoV-2. This antibody, known for its cancer-fighting properties, shows potential for further development in tackling COVID-19. Senior Medical Consultant Dr. Navpaul Singh emphasized that less viral load correlates with reduced patient symptoms, suggesting PTB could be used in combination therapies. The company is also advancing its Phase I Brain Cancer Clinical Trial.

Nascent Biotech, Inc. (OTCQB:NBIO) announced crucial additions to its team as it prepares for Phase One clinical trials of its monoclonal antibody, Pritumumab (PTB), aimed at treating brain cancer. Effective November 1, 2020, Douglas Karas steps in as Chief Operating Officer, while Dr. Ivan Babic joins as Consulting Director of Research. These changes aim to enhance the company’s expertise in oncology. The trials are set to advance Nascent Biotech’s position in the cancer treatment sector.

Nascent Biotech, Inc. (OTCQB:NBIO) has successfully reduced its liabilities, decreasing convertible note principal from $161,250 to $11,250, achieving a total reduction of $150,000. This debt reduction strengthens the company's financial position, allowing it to focus on upcoming clinical trials for its lead candidate, Pritumumab (PTB), targeting brain and pancreatic cancers. The trials are set to begin soon, with additional development for COVID-19 treatments also underway.